Jonas Bystrom1, Felix I L Clanchy2, Taher E Taher3, Mohammed Al-Bogami4, Voon H Ong5, David J Abraham5, Richard O Williams2, Rizgar A Mageed1. 1. William Harvey Research Institute, Queen Mary University of London, London, UK. 2. Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 3. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. 4. Radiology Department, Alnakheel Medical Centre, Riyadh, Kingdom of Saudi Arabia. 5. Centre for Rheumatology and Connective Tissue Diseases, University College London, Royal Free Hospital, London, UK.
Abstract
BACKGROUND: Th17 cells have nonredundant roles in maintaining immunity, particularly at mucosal surfaces. These roles are achieved principally through the production of cytokines and the recruitment of other immune cells to maintain the integrity of mucosal barriers and prevent the dissemination of microorganisms. Th17 cells are heterogeneous and exhibit a considerable degree of plasticity. This allows these cells to respond to changing environmental challenges. However, Th17 cells also play pro-inflammatory roles in chronic autoimmune diseases. The trigger(s) that initiate these Th17 responses in chronic autoimmune diseases remain unclear. DESIGN: In this report, we provide an overview of studies involving animal models, patient data, genome wide association studies and clinical trials targeting IL-17 for treatment of patients to gain a better understanding of the pathogenic roles of Th17 cells play in a range of autoimmune diseases. RESULTS: The report sheds light on likely triggers that initiate or perpetuate Th17 responses that promote chronic inflammation and autoimmunity. The divergent effects of tumour necrosis factor alpha blockade on Th17 cells in patients, is explored. Furthermore, we highlight the role of Th17 cells in inducing autoreactive B cells, leading to autoantibody production. Pathogenic bacterial species can change Th17 cell phenotype and responses. These findings provide insights into how Th17 cells could be induced to promoting autoimmune disease pathogenesis. CONCLUSION: This article provides an overview of the distinct roles Th17 cells play in maintaining immunity at mucosal surfaces and in skin mucosa and how their functional flexibility could be linked with chronic inflammation in autoimmune rheumatic diseases.
BACKGROUND: Th17 cells have nonredundant roles in maintaining immunity, particularly at mucosal surfaces. These roles are achieved principally through the production of cytokines and the recruitment of other immune cells to maintain the integrity of mucosal barriers and prevent the dissemination of microorganisms. Th17 cells are heterogeneous and exhibit a considerable degree of plasticity. This allows these cells to respond to changing environmental challenges. However, Th17 cells also play pro-inflammatory roles in chronic autoimmune diseases. The trigger(s) that initiate these Th17 responses in chronic autoimmune diseases remain unclear. DESIGN: In this report, we provide an overview of studies involving animal models, patient data, genome wide association studies and clinical trials targeting IL-17 for treatment of patients to gain a better understanding of the pathogenic roles of Th17 cells play in a range of autoimmune diseases. RESULTS: The report sheds light on likely triggers that initiate or perpetuate Th17 responses that promote chronic inflammation and autoimmunity. The divergent effects of tumour necrosis factor alpha blockade on Th17 cells in patients, is explored. Furthermore, we highlight the role of Th17 cells in inducing autoreactive B cells, leading to autoantibody production. Pathogenic bacterial species can change Th17 cell phenotype and responses. These findings provide insights into how Th17 cells could be induced to promoting autoimmune disease pathogenesis. CONCLUSION: This article provides an overview of the distinct roles Th17 cells play in maintaining immunity at mucosal surfaces and in skin mucosa and how their functional flexibility could be linked with chronic inflammation in autoimmune rheumatic diseases.
Authors: Robyn M Jong; Erik Van Dis; Samuel B Berry; Xammy Nguyenla; Alexander Baltodano; Gabrielle Pastenkos; Chenling Xu; Douglas Fox; Nir Yosef; Sarah M McWhirter; Sarah A Stanley Journal: J Immunol Date: 2021-12-29 Impact factor: 5.422
Authors: Sonwabile Dzanibe; Katie Lennard; Agano Kiravu; Melanie S S Seabrook; Berenice Alinde; Susan P Holmes; Catherine A Blish; Heather B Jaspan; Clive M Gray Journal: J Immunol Date: 2021-11-24 Impact factor: 5.422
Authors: Marcos Luiz Gaia Carvalho; Luiz Fábio Magno Falcão; Jeferson da Costa Lopes; Caio Cesar Henriques Mendes; Fábio Alves Olímpio; Vanessa do Socorro Cabral Miranda; Lais Carneiro Dos Santos; Daniel Dias Pinheiro de Moraes; Marcos Virgilio Bertonsin Filho; Luccas Delgado da Costa; Raimunda do Socorro da Silva Azevedo; Ana Cecília Ribeiro Cruz; Vanessa Costa Alves Galúcio; Lívia Caricio Martins; Maria Irma Seixas Duarte; Arnaldo Jorge Martins Filho; Jorge Rodrigues de Sousa; Pedro Fernando da Costa Vasconcelos; Juarez Antônio Simões Quaresma Journal: Cells Date: 2022-06-28 Impact factor: 7.666
Authors: Hubaida Fuseini; Jacqueline-Yvonne Cephus; Pingsheng Wu; J Brooke Davis; Diana C Contreras; Vivek D Gandhi; Jeffrey C Rathmell; Dawn C Newcomb Journal: Front Immunol Date: 2019-11-27 Impact factor: 7.561
Authors: Agnieszka Paradowska-Gorycka; Anna Wajda; Ewa Rzeszotarska; Tomasz Kmiolek; Barbara Stypinska; Ewa Dudek; Katarzyna Romanowska-Prochnicka; Piotr Syrowka Journal: Int J Mol Sci Date: 2022-07-18 Impact factor: 6.208